Composition for detecting and distinguishing viral meningitis related pathogens

Through the use of multiple fluorescence PCR analysis methods and specific upstream and downstream primer probe compositions, the difficulties in distinguishing and detecting multiple pathogens of viral meningitis are solved, and rapid and accurate diagnosis is achieved, and treatment delay is shortened.

CN118932113AActive Publication Date: 2024-11-12XUANWU HOSPITAL OF CAPITAL UNIV OF MEDICAL SCI +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411065387.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-12
Estimated Expiration
2044-08-05

AI Technical Summary

Technical Problem

The prior art is difficult to quickly and accurately distinguish and detect various pathogens that cause viral meningitis, resulting in long diagnosis time and delayed treatment.

Method used

By using multiple fluorescence PCR analysis method, a composition containing upstream and downstream primers and probes is provided by detecting different sites, which can simultaneously detect and distinguish Alongshan virus, novel Bunia virus, and rabies virus in a single tube reaction system. , Ecovirus, measles virus and B encephalitis virus, and combined with internal standards to improve the sensitivity and accuracy of detection.

Benefits of technology

Simultaneous detection and distinction of at least four pathogens has been achieved, which improves the speed and accuracy of diagnosis, shortens the time for clinicians to diagnose patients' conditions, and speeds up the implementation of treatment measures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932113A_ABST
    Figure CN118932113A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of molecular biological detection, and particularly relates to viral meningitis related pathogens. Comprising a composition for detecting and distinguishing herpes simplex virus type 1 / 2 (HSV 1 / 2), human cytomegalovirus (HCMV), EB virus (EBV), varicella zoster virus (VZV), human herpes virus type 6 (HHV6), enterovirus (EV), Alongshan virus (ALSV), novel bunyavirus (SFTSV), rabies virus (RV), echovirus (ECHOV), measles virus (MeV) and Japanese encephalitis virus (JEV). Meanwhile, the detection sensitivity of the composition is higher and reaches 100 copies / mL, and the detection is more accurate.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of molecular biological detection, and specifically, relates to a composition and use for detecting and distinguishing viral meningitis-related pathogens, including herpes simplex virus type 1 / 2 (HSV 1 / 2), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), varicella-zoster virus (VZV), human herpesvirus type 6 (HHV6), enterovirus (EV), Alonshan virus (ALSV), novel bunyavirus (SFTSV), rabies virus (RV), echovirus (ECHOV), measles virus (MeV), and Japanese encephalitis virus (JEV). Background Art

[0002] Herpes simplex virus (HSV) is a typical representative of herpes viruses. It is a double-stranded DNA virus with an envelope structure that can cause a variety of human diseases, such as gingivostomatitis, keratoconjunctivitis, encephalitis, and reproductive system infections and neonatal infections. It can be divided into two serotypes, HSV-1 and HSV-2, based on different antigenicity. Severe infections can cause dangerous diseases such as sporadic encephalitis.

[0003] Human cytomegalovirus (HCMV), also known as human herpesvirus type 5, is a double-stranded DNA virus. HCMV infection can manifest as asymptomatic, systemic symptoms, or tissue invasive diseases. After the initial infection in people with normal immune function, the virus can remain latent in the host for life. When the host's immune function is weakened, the virus can reactivate and cause serious diseases. Among them, the central nervous system is a common system for HCMV infection in individuals with normal immune function.

[0004] Epstein-Barr virus (EBV), also known as human herpesvirus type 4, is the only lymphofollicular DNA virus in the γ subfamily of the herpesviridae family that can cause human infection. It is usually divided into two types, A and B, based on the different expressions of the EBNA2 gene. The clinical symptoms vary in severity and manifestations, and different system infections can have corresponding clinical characteristics. EBV is one of the common pathogens of viral infections of the central nervous system in children. Adult EBV meningoencephalitis is relatively rare. It is an infectious disease caused by EBV infection that causes acute inflammation of the meninges and brain parenchyma. The main clinical manifestations are fever, headache and meningeal irritation signs.

[0005] Varicella-zoster virus (VZV), also known as human herpes virus-3 (HHV3), is a double-stranded DNA virus of the α-herpesvirus subfamily of the herpesviridae family. It is neuroinvasive, and under natural conditions, humans are the only host of VZV. The initial infection with VZV can cause chickenpox, after which the virus remains latent in the ganglia of cranial nerves, dorsal roots, and autonomic nerves for a long time. Reactivation can cause herpes zoster and can also cause central nervous system (CNS) infections, including meningitis and encephalitis. Epidemiological studies have shown that the incidence of chickenpox has decreased significantly since the application of VZV live attenuated vaccines, but the complications of VZV-related central nervous system diseases are more common and diverse than before.

[0006] Human herpesvirus 6 (HHV6) is a double-stranded DNA virus of the herpesviridae family and the betaherpesvirinae subfamily. Based on the differences in antigenicity, host range, restriction endonuclease map and gene structure of HHV6 isolates, the virus is divided into two viruses: HHV6A and HHV6B. HHV6 can cause infantile exanthema and is associated with lesions of the nervous system. Most newborns can obtain anti-HHV6 specific antibodies from their mothers. With the increase of age, the titer of maternal antibodies decreases, and the primary infection rate gradually increases, reaching its peak 6 to 9 months after birth.

[0007] Enterovirus (EV) is an RNA virus of the genus Enterovirus in the family Picornaviridae. Enterovirus is one of the main viruses that cause viral encephalitis in my country. The disease mainly occurs in children, and the epidemic period is mainly in summer and autumn. It is generally sporadic, and rarely occurs in epidemics. The clinical manifestations of the infected are mild, such as fatigue, weakness, and low fever. In severe cases, the infection may cause systemic infection and damage to important organs such as the brain and spinal cord.

[0008] Alongshan virus (ALSV) is an RNA virus of the Flaviviridae family and the Jingmenvirus genus. ALSV is caused by tick bites, and the main clinical symptoms include fever, fatigue, headache, nausea, impaired consciousness, myalgia / arthralgia, lack of energy, rash, etc. The disease is called "Alongshan fever".

[0009] The novel Bunyavirus (SFTSV), also known as fever with thrombocytopenia syndrome virus, is a new RNA virus of the genus Phlebovirus in the family Bunyaviridae. It is mainly transmitted by ticks and can cause influenza-like or dengue fever-like diseases, hemorrhagic fever and encephalitis in humans.

[0010] Rabies virus (RV) is a RNA virus of the Rhabdoviridae family and the genus Lyssavirus. The pathological changes of infected people are mainly acute diffuse encephalomyelitis, especially in the dorsal root ganglia and spinal cord segments corresponding to the bite site, the hippocampus of the brain, and the medulla oblongata, pons, cerebellum, etc. The brain parenchyma is congested, edematous and has microhemorrhages. Nonspecific degeneration and inflammatory changes can be seen under the microscope, such as vacuolization of nerve cells, hyaline degeneration and chromatin decomposition, and perivascular mononuclear cell infiltration.

[0011] Echovirus (ECHOV) is a subtype of the genus Enterovirus in the family Parvoviridae. Its morphological structure and physical and chemical properties are similar to those of poliovirus and Coxsackievirus. It most commonly infects the central nervous system, with clinical symptoms such as fever, headache, nausea, vomiting, diarrhea, drowsiness, impaired consciousness, decreased attention, inattention, memory loss, coma, convulsions, impaired consciousness, somatic disorders, etc. In addition, there may be focal manifestations such as hemisensory disorders, hemiplegia, and focal neurological deficits.

[0012] Measles virus (MeV) is a RNA virus of the Paramyxoviridae family and the Morbillivirus genus. Subacute sclerosing panencephalitis (SSPE) is a late-onset complication of acute measles infection, which is mainly manifested by the progressive decline of brain function, severe disease and poor prognosis.

[0013] Japanese encephalitis virus (JEV) is an RNA virus of the family Togaviridae and genus Flavivirus. It is mainly transmitted by mosquitoes or blood-sucking insects. After mosquitoes carrying JEV bite humans, the virus first proliferates in mononuclear macrophages and then enters the bloodstream, causing an immune response. Antibodies bind to viral antigens and are deposited in the brain parenchyma and vascular endothelial cells, activating complement and causing immune damage, which is mainly manifested as high fever, impaired consciousness, convulsions, respiratory failure and meningeal irritation.

[0014] Since there are many types of pathogens that cause viral encephalitis, with wide transmission routes, a large transmission range, and strong infectivity, it is difficult to distinguish the types of pathogens only from clinical manifestations and signs. For viral encephalitis caused by different pathogens, the treatment plans are also different. Therefore, there is a need in this field for a product that can simply and quickly detect the above pathogens with high sensitivity and good specificity, providing clinicians with a relatively sufficient basis for rapid diagnosis and exclusion of different pathogen infections, shortening the time for clinicians to diagnose the patient's condition, and speeding up the implementation of treatment measures for patients. Summary of the invention

[0015] In view of this, in a first aspect, the present invention provides a composition for detecting and distinguishing viral meningitis-related pathogens, comprising a first nucleic acid composition, wherein:

[0016] The first nucleic acid composition includes upstream and downstream primers and probes for detecting at least 4 of the following pathogens:

[0017] Upstream and downstream primers and probes for detecting Alongshan virus as shown in SEQ ID NOs: 1 to 3;

[0018] Upstream and downstream primers and probes for detecting novel bunyaviruses as shown in SEQ ID NOs: 4 to 6;

[0019] Upstream and downstream primers and probes for detecting rabies virus as shown in SEQ ID NOs: 7 to 9;

[0020] Upstream and downstream primers and probes for detecting echovirus as shown in SEQ ID NOs: 10 to 12;

[0021] Upstream and downstream primers and probes for detecting measles virus as shown in SEQ ID NOs: 13 to 15; or

[0022] The upstream and downstream primers and probes for detecting Japanese encephalitis virus are shown in SEQ ID NOs: 16-18.

[0023] The combined test composition provided by the present invention mainly utilizes a multiplex fluorescent PCR analysis method to detect and distinguish viral meningitis-related pathogens by detecting different sites, thereby simultaneously realizing the detection and distinction of at least 4 pathogens in Alongshan virus, new bunyavirus, rabies virus, echovirus, measles virus, and Japanese encephalitis virus in a single-tube reaction system, so as to provide a targeted strategy for subsequent treatment. At the same time, the composition of the present invention has a higher sensitivity of detection, reaching 100 copies / mL, and the detection is more accurate, providing a more sufficient basis for rapid diagnosis for clinicians, shortening the time for clinicians to diagnose the patient's condition, and accelerating the implementation of treatment measures for patients.

[0024] Furthermore, the present invention provides a composition for detecting and distinguishing viral meningitis-related pathogens, comprising a first nucleic acid composition, wherein:

[0025] The first nucleic acid composition comprises:

[0026] Upstream and downstream primers and probes for detecting Alongshan virus as shown in SEQ ID NOs: 1 to 3; and

[0027] Upstream and downstream primers and probes for detecting at least 3 of the following pathogens:

[0028] Upstream and downstream primers and probes for detecting novel bunyaviruses as shown in SEQ ID NOs: 4 to 6;

[0029] Upstream and downstream primers and probes for detecting rabies virus as shown in SEQ ID NOs: 7 to 9;

[0030] Upstream and downstream primers and probes for detecting echovirus as shown in SEQ ID NOs: 10 to 12;

[0031] Upstream and downstream primers and probes for detecting measles virus as shown in SEQ ID NOs: 13 to 15; or

[0032] The upstream and downstream primers and probes for detecting Japanese encephalitis virus are shown in SEQ ID NOs: 16-18.

[0033] Furthermore, the present invention provides a composition for detecting and distinguishing viral meningitis-related pathogens, comprising a first nucleic acid composition, wherein:

[0034] The first nucleic acid composition includes upstream and downstream primers and probes for detecting the following pathogens:

[0035] Upstream and downstream primers and probes for detecting Alongshan virus as shown in SEQ ID NOs: 1 to 3;

[0036] Upstream and downstream primers and probes for detecting novel bunyaviruses as shown in SEQ ID NOs: 4 to 6;

[0037] Upstream and downstream primers and probes for detecting rabies virus as shown in SEQ ID NOs: 7 to 9;

[0038] Upstream and downstream primers and probes for detecting echovirus as shown in SEQ ID NOs: 10 to 12;

[0039] Upstream and downstream primers and probes for detecting measles virus as shown in SEQ ID NOs: 13 to 15; and

[0040] The upstream and downstream primers and probes for detecting Japanese encephalitis virus are shown in SEQ ID NOs: 16-18.

[0041] Furthermore, the composition of the present invention further comprises: a second nucleic acid composition, wherein the second nucleic acid composition comprises upstream and downstream primers and probes for detecting at least 4 of the following pathogens:

[0042] Upstream and downstream primers and probes for detecting Epstein-Barr virus as shown in SEQ ID NOs: 19 to 21;

[0043] Upstream and downstream primers and probes for detecting varicella-zoster virus as shown in SEQ ID NOs: 22 to 24;

[0044] Upstream and downstream primers and probes for detecting human cytomegalovirus as shown in SEQ ID NOs: 25 to 27;

[0045] Upstream and downstream primers and probes for detecting human herpesvirus type 6 as shown in SEQ ID NOs: 28 to 30;

[0046] Upstream and downstream primers and probes for detecting herpes simplex virus type 1 / 2 as shown in SEQ ID NOs: 31 to 33; or

[0047] The upstream and downstream primers and probes for detecting enterovirus are shown in SEQ ID NOs: 34-36.

[0048] Furthermore, the composition of the present invention further comprises: a second nucleic acid composition, wherein the second nucleic acid composition comprises upstream and downstream primers and probes for detecting the following pathogens:

[0049] Upstream and downstream primers and probes for detecting Epstein-Barr virus as shown in SEQ ID NOs: 19 to 21;

[0050] Upstream and downstream primers and probes for detecting varicella-zoster virus as shown in SEQ ID NOs: 22 to 24;

[0051] Upstream and downstream primers and probes for detecting human cytomegalovirus as shown in SEQ ID NOs: 25 to 27;

[0052] Upstream and downstream primers and probes for detecting human herpesvirus type 6 as shown in SEQ ID NOs: 28 to 30;

[0053] Upstream and downstream primers and probes for detecting herpes simplex virus type 1 / 2 as shown in SEQ ID NOs: 31 to 33; and

[0054] The upstream and downstream primers and probes for detecting enterovirus are shown in SEQ ID NOs: 34-36.

[0055] Furthermore, the composition includes upstream and downstream primers and probes for detecting the internal standard.

[0056] In some specific embodiments, the internal standard is a human internal standard gene. In a specific embodiment, the internal standard is a human housekeeping gene.

[0057] Furthermore, the fluorescent groups of the probes for detecting different pathogens in the first nucleic acid composition of the present invention are different from each other and do not interfere with each other.

[0058] Furthermore, the fluorescent groups of the probes for detecting different pathogens in the second nucleic acid composition of the present invention are different from each other and do not interfere with each other.

[0059] In this article, "different from each other and not interfering with each other" means that the fluorescent groups used in each probe in the composition are different and will not affect each other's detection, that is, different channels can be used for detection. For example, ATTO425, Quasar705, FAM, HEX, ROX, CY5 and CY5.5 can be used. The absorbance values ​​of these groups are not close, and different channels can be selected, so they will not interfere with each other.

[0060] Further, in some embodiments, the composition of the present invention may include one or more pairs of the above primer and probe pairs. In the present invention, "pair" refers to upstream and downstream primers and probes that match each other for detecting a target.

[0061] Each nucleic acid composition of the present invention can be arbitrarily combined into any combination of detection corresponding to 6 targets. Those skilled in the art can combine as needed to detect which targets, that is, to combine the primers and probe pairs corresponding to the targets. These combinations are all included in the present invention.

[0062] For example, it may include any 5 pairs of the above 6 pairs of primers and probes, it may include any 4 pairs of the above 6 pairs of primers and probes, it may include any 3 pairs of the above 6 pairs of primers and probes, it may include any 2 pairs of the above 6 pairs of primers and probes, or it may include any 1 pair of the above 6 pairs of primers and probes.

[0063] In some specific embodiments, the compositions of the present invention are used for fluorescent PCR.

[0064] In a specific embodiment, the fluorescent reporter group of the probe for Alongshan virus is FAM; the fluorescent reporter group of the probe for the novel Bunyavirus is HXE; the fluorescent reporter group of the probe for rabies virus is ROX; the fluorescent reporter group of the probe for echovirus is CY5; the fluorescent reporter group of the probe for measles virus is ATTO 425; and the fluorescent reporter group of the probe for Japanese encephalitis virus is Quasar 705.

[0065] In a specific embodiment, the fluorescent reporter group of the probe for Epstein-Barr virus is FAM; the fluorescent reporter group of the probe for varicella-zoster virus is HXE; the fluorescent reporter group of the probe for human cytomegalovirus is ROX; the fluorescent reporter group of the probe for human herpes virus type 6 is CY5; the fluorescent reporter group of the probe for herpes simplex virus type 1 / 2 is ATTO425; and the fluorescent reporter group of the probe for enterovirus is Quasar 705.

[0066] Furthermore, the 3' end of the probe also has a non-fluorescent quencher.

[0067] Furthermore, the 3' end of the probe also has a quencher group, such as MGB, Dabcyl BHQ-0, BHQ1, BHQ2 or BHQ3.

[0068] Furthermore, the dosage of a single primer in the composition is 0.2-0.5 μM; the dosage of a single probe in the composition is 0.1-0.2 μM.

[0069] In a specific embodiment, each component of the composition of the present invention is present in a separate package.

[0070] In a particular embodiment, the components of the composition of the present invention are present in the same package.

[0071] Furthermore, the components of the composition of the present invention are present in a mixed form.

[0072] In a second aspect, the present invention provides use of the above-mentioned composition of the present invention in preparing a kit for detecting and differentiating viral meningitis-related pathogens.

[0073] In a third aspect, the present invention provides a kit for detecting and differentiating viral meningitis-related pathogens, the kit comprising the composition of the present invention as described above.

[0074] Furthermore, the kit also includes a negative quality control product and a positive quality control product.

[0075] In a specific embodiment, the negative control product is at least one of DEPC H2O, physiological saline, and internal standard gene. The positive control product is at least one of pseudovirus or fragment gene of the virus described in the present invention.

[0076] Furthermore, the kit also includes a nucleic acid amplification reagent.

[0077] Furthermore, the amplification reagent includes dNTP(U)s, PCR buffer, reverse transcriptase, DNA polymerase, UNG enzyme, and Mg 2+ At least one of .

[0078] Furthermore, the kit also includes: a nucleic acid releasing reagent and a nucleic acid extracting reagent.

[0079] Furthermore, the concentration of the DNA polymerase is 3U / reaction to 15U / reaction, for example, the DNA polymerase may be Taq enzyme; the concentration of the reverse transcriptase is 4U / reaction to 12U / reaction, for example, the reverse transcriptase may be Neoscript RT enzyme; the concentration of the UNG enzyme is 0.4U-2U / reaction.

[0080] In a specific embodiment, the kit of the present invention comprises: Taq enzyme, reverse transcriptase, UNG enzyme, Mg2+, dNTP(U)s, primers, probe and PCR buffer.

[0081] PCR buffer is composed of Tris-HCl, KCl, Triton X-100, etc. The total volume in a single PCR reaction tube is generally 20 μl to 200 μl.

[0082] In a fourth aspect, a method for detecting and distinguishing viral meningitis-related pathogens is provided, the method comprising the following steps:

[0083] 1) Extracting nucleic acid from the sample to be tested;

[0084] 2) using the composition of the present invention or the kit of the present invention as described above to perform fluorescent quantitative PCR on the nucleic acid obtained in step 1);

[0085] 3) Obtain and analyze the results.

[0086] In the present invention, the sample used for detection can be serum, blood, cerebrospinal fluid, etc., but is not limited thereto.

[0087] Furthermore, the reaction conditions of the fluorescent quantitative PCR are:

[0088] cDNA reverse transcription and UNG enzyme reaction, the temperature is 50-65℃, the time is 2-5 minutes, 1 cycle; cDNA pre-denaturation, the temperature is 90-99℃, the time is 5-120 seconds, 1 cycle; denaturation, the temperature is 94℃, the time is 5-20 seconds, annealing, the temperature is 55℃-60℃, the time is 10-60 seconds, 30-50 cycles, and fluorescence is collected.

[0089] In a specific embodiment, a method for detecting and distinguishing viral meningitis-related pathogens for non-diagnostic purposes is provided, the method comprising the following steps:

[0090] 1) Extracting nucleic acid from the sample to be tested;

[0091] 2) using the composition of the present invention or the kit of the present invention as described above to perform fluorescent quantitative PCR on the nucleic acid obtained in step 1);

[0092] 3) Obtain and analyze the results.

[0093] Furthermore, the reaction conditions of the fluorescent quantitative PCR are:

[0094] cDNA reverse transcription and UNG enzyme reaction, the temperature is 50-65℃, the time is 2-5 minutes, 1 cycle; cDNA pre-denaturation, the temperature is 90-99℃, the time is 5-120 seconds, 1 cycle; denaturation, the temperature is 95℃, the time is 5-20 seconds, annealing, the temperature is 55℃-60℃, the time is 10-60 seconds, 30-50 cycles, and fluorescence is collected.

[0095] In a specific embodiment, a composition is provided for preparing a composition for detecting and distinguishing viral meningitis-related pathogens, wherein the use detects the following steps:

[0096] 1) Extracting nucleic acid from the sample to be tested;

[0097] 2) using the composition of the present invention or the kit of the present invention as described above to perform fluorescent quantitative PCR on the nucleic acid obtained in step 1);

[0098] 3) Obtain and analyze the results.

[0099] Furthermore, the reaction conditions of the fluorescent quantitative PCR are:

[0100] cDNA reverse transcription and UNG enzyme reaction, the temperature is 50-65℃, the time is 2-5 minutes, 1 cycle; cDNA pre-denaturation, the temperature is 90-99℃, the time is 5-120 seconds, 1 cycle; denaturation, the temperature is 94℃, the time is 5-20 seconds, annealing, the temperature is 55℃-60℃, the time is 10-60 seconds, 30-50 cycles, and fluorescence is collected. BRIEF DESCRIPTION OF THE DRAWINGS

[0101] Figures 1 to 4 A graph showing the test results of different sample combinations of the composition of the present invention;

[0102] Figures 5 to 16 The sensitivity result diagram of the composition of the present invention (Alongshan virus, new bunyavirus, rabies virus, echovirus, measles virus, Japanese encephalitis virus, Epstein-Barr virus, varicella-zoster virus, human cytomegalovirus, human herpes virus type 6, herpes simplex virus type 1 / 2, and enterovirus, respectively);

[0103] Fig.17 This is a graph showing the specificity results of the first nucleic acid composition of the composition of the present invention;

[0104] Fig.18 This is a graph showing the specificity results of the second nucleic acid composition of the present invention. DETAILED DESCRIPTION

[0105] The present invention will be described in detail below in conjunction with specific embodiments and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific embodiments and examples are used to illustrate the present invention, rather than to limit the present invention.

[0106] Example 1: Primers and probes used in the present invention

[0107] Table 1

[0108]

[0109]

[0110] Note: R is a degenerate base of A and G.

[0111] Among them, the fluorescent reporter group of the probe for Alongshan virus is FAM; the fluorescent reporter group of the probe for the new Bunyavirus is HXE; the fluorescent reporter group of the probe for rabies virus is ROX; the fluorescent reporter group of the probe for echovirus is CY5; the fluorescent reporter group of the probe for measles virus is ATTO 425; and the fluorescent reporter group of the probe for Japanese encephalitis virus is Quasar 705.

[0112] Among them, the fluorescent reporter group of the Epstein-Barr virus probe is FAM; the fluorescent reporter group of the varicella-zoster virus probe is HXE; the fluorescent reporter group of the human cytomegalovirus probe is ROX; the fluorescent reporter group of the human herpes virus type 6 probe is CY5; the fluorescent reporter group of the herpes simplex virus type 1 / 2 probe is ATTO 425; and the fluorescent reporter group of the enterovirus probe is Quasar 705.

[0113] Example 2: Method for detecting and distinguishing pathogens related to viral meningitis

[0114] The sample detected by the present invention is cerebrospinal fluid. The real-time fluorescence PCR reaction system is configured according to the following Table 2. According to the number of samples to be tested, positive controls, and negative controls, the corresponding amount of the first nucleic acid composition reaction solution and the enzyme mixture are taken in proportion (38 μL / person of the first nucleic acid composition reaction solution + 2 μL / person of the enzyme mixture), and the mixture is fully mixed to form the first nucleic acid composition reaction system, and centrifuged at 2000 rpm for 10 seconds for use;

[0115] Take the corresponding amount of the second nucleic acid composition reaction solution and the enzyme mixture according to the ratio (38 μL of the second nucleic acid composition reaction solution / person+2 μL of the enzyme mixture / person), mix them thoroughly to form a second nucleic acid composition reaction system, centrifuge at 2000 rpm for 10 seconds and set aside.

[0116] Take 200μL of the sample to be tested, negative control, and positive control into a 1.5mL centrifuge tube, and use the nucleic acid extraction or purification reagent of Shengxiang Biotechnology Co., Ltd. to extract nucleic acid according to its instructions. Pipette 10μL of the above-treated sample, negative control, and positive control and add them to the corresponding 0.2mL PCR reaction tubes, add 40μL of PCR mixture to each tube, and cover the tube cap.

[0117] Table 2

[0118]

[0119]

[0120] Preparation of enzyme mixture:

[0121] The enzyme mixture consists of Neoscript RT reverse transcriptase, UNG enzyme and H-Taq enzyme. H-Taq enzyme (5U / μL), Neoscript RT enzyme (40U / μL) and UNG enzyme (2U / μL) are mixed in a certain ratio (1.5μL H-Taq enzyme, 0.3μL Neoscript RT enzyme and 0.2μL UNG enzyme per person). The PCR amplification program is set as shown in Table 3 below:

[0122] Table 3

[0123]

[0124] If the sample has an obvious S-shaped amplification curve in the FAM, HEX, ROX, CY5, Atto425 and Quasar705 channels and the Ct value is ≤40, it is judged as positive; if the sample has no amplification curve (No Ct) or the Ct value is greater than 40 in the FAM, HEX, ROX, CY5, 425, 705 channels, it is judged as negative; the details are shown in Table 4.

[0125] Table 4. Interpretation of test results

[0126]

[0127]

[0128] Example 3: Test results of the test samples of the composition of the present invention

[0129] The primers and probes shown in Example 1 were used to verify the samples of Alongshan virus, new bunyavirus, rabies virus, echovirus, measles virus, and Japanese encephalitis virus involved in the first nucleic acid composition according to the method of Example 2. The results showed that the composition of the present invention can detect and distinguish any combination of the above pathogens. For example, the composition of the present invention detects and distinguishes the pathogen combination:

[0130] Alongshan virus, new Bunyavirus, measles virus, Japanese encephalitis virus ( Figure 1 );

[0131] Arongshan virus, new Bunyavirus, rabies virus, echovirus, measles virus ( Figure 2 );

[0132] Alongshan virus, new Bunyavirus, rabies virus, echovirus, measles virus, Japanese encephalitis virus ( Figure 3 ), these figures can prove that the first nucleic acid composition of the present invention can amplify any of the above 6 targets in 6-plex PCR at one time, and can be distinguished using a 6-channel PCR instrument.

[0133] Further, the herpes simplex virus type 1 / 2 (HSV 1 / 2), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), varicella-zoster virus (VZV), human herpes virus type 6 (HHV6), and enterovirus (EV) involved in the second nucleic acid composition are verified, as shown in the following example: Figure 4 As shown, it is proved that the second nucleic acid composition of the present invention can amplify the 6-plex PCR of the above 6 targets at one time, and can be distinguished using a 6-channel PCR instrument.

[0134] Example 4: Sensitivity of the composition of the present invention

[0135] Using the first and second nucleic acid compositions in Example 1 of the present invention, LOD (sensitivity) detection was performed on each target to simulate clinical samples and multiplex PCR detection was performed on a fluorescent quantitative PCR instrument. Figures 5 to 16 As shown, it is shown that each channel can still accurately detect samples as low as 100 copies / mL, indicating that the sensitivity of the composition of the present invention is 100 copies / mL.

[0136] Example 5. Specificity of the composition of the present invention

[0137] The composition of the present invention has no cross-reaction with common pathogens and other pathogens with similar infection symptoms (such as yellow fever virus, mumps virus, Zika virus, chikungunya virus, adenovirus, human parvovirus, West Nile virus, forest encephalitis virus, rubella virus, etc.). Fig.17 and 18 As shown, it is shown that the composition of the present invention has good specificity.

[0138] Example 6: Anti-interference performance of the composition of the present invention

[0139] The composition of Example 2 was analyzed by adding interfering substances. The experimental results showed that a certain concentration of dexamethasone, beclomethasone, mometasone, zanamivir, cefmenoxime hydrochloride, histamine hydrochloride, azithromycin, tobramycin, ribavirin, mupirocin, fluticasone, budesonide, triamcinolone acetonide, heme, purified mucin, anhydrous ethanol and other potential PCR inhibitors / interfering substances had no obvious effect on the kit. The amplification results of the PCR reaction solution in the presence of infectious substances are specifically shown in Table 5 (first nucleic acid composition) and Table 6 (second nucleic acid composition) below.

[0140] Table 5

[0141]

[0142] Table 6

[0143]

[0144]

Claims

1. A composition for detecting and distinguishing viral meningitis-related pathogens, comprising a first nucleic acid composition, wherein: The first nucleic acid composition includes upstream and downstream primers and probes for detecting at least 4 of the following pathogens: Upstream and downstream primers and probes for detecting Alongshan virus as shown in SEQ ID NOs: 1 to 3; Upstream and downstream primers and probes for detecting novel bunyaviruses as shown in SEQ ID NOs: 4 to 6; Upstream and downstream primers and probes for detecting rabies virus as shown in SEQ ID NOs: 7 to 9; Upstream and downstream primers and probes for detecting echovirus as shown in SEQ ID NOs: 10 to 12; Upstream and downstream primers and probes for detecting measles virus as shown in SEQ ID NOs: 13 to 15; or The upstream and downstream primers and probes for detecting Japanese encephalitis virus are shown in SEQ ID NOs: 16-18.

2. The composition according to claim 1, characterized in that The composition comprises a first nucleic acid composition, wherein The first nucleic acid composition comprises: Upstream and downstream primers and probes for detecting Alongshan virus as shown in SEQ ID NOs: 1 to 3; and Upstream and downstream primers and probes for detecting at least 3 of the following pathogens: Upstream and downstream primers and probes for detecting novel bunyavirus as shown in SEQ ID NOs: 4 to 6; Upstream and downstream primers and probes for detecting rabies virus as shown in SEQ ID NOs: 7 to 9; Upstream and downstream primers and probes for detecting echovirus as shown in SEQ ID NOs: 10 to 12; Upstream and downstream primers and probes for detecting measles virus as shown in SEQ ID NOs: 13 to 15; or The upstream and downstream primers and probes for detecting Japanese encephalitis virus are shown in SEQ ID NOs: 16-18.

3. The composition according to claim 1 or 2, characterized in that The composition further comprises: a second nucleic acid composition, wherein The second nucleic acid composition includes upstream and downstream primers and probes for detecting at least 4 of the following pathogens: Upstream and downstream primers and probes for detecting Epstein-Barr virus as shown in SEQ ID NOs: 19 to 21; Upstream and downstream primers and probes for detecting varicella-zoster virus as shown in SEQ ID NOs: 22 to 24; Upstream and downstream primers and probes for detecting human cytomegalovirus as shown in SEQ ID NOs: 25 to 27; Upstream and downstream primers and probes for detecting human herpesvirus type 6 as shown in SEQ ID NOs: 28 to 30; Upstream and downstream primers and probes for detecting herpes simplex virus type 1 / 2 as shown in SEQ ID NOs: 31 to 33; or The upstream and downstream primers and probes for detecting enterovirus are shown in SEQ ID NOs: 34-36.

4. The composition according to claim 3, characterized in that The composition further comprises: a second nucleic acid composition, wherein The second nucleic acid composition includes upstream and downstream primers and probes for detecting the following pathogens: Upstream and downstream primers and probes for detecting Epstein-Barr virus as shown in SEQ ID NOs: 19 to 21; Upstream and downstream primers and probes for detecting varicella-zoster virus as shown in SEQ ID NOs: 22 to 24; Upstream and downstream primers and probes for detecting human cytomegalovirus as shown in SEQ ID NOs: 25 to 27; Upstream and downstream primers and probes for detecting human herpesvirus type 6 as shown in SEQ ID NOs: 28 to 30; Upstream and downstream primers and probes for detecting herpes simplex virus type 1 / 2 as shown in SEQ ID NOs: 31 to 33; and The upstream and downstream primers and probes for detecting enterovirus are shown in SEQ ID NOs: 34-36.

5. The composition according to claim 4, characterized in that The fluorescent groups of the probes for detecting different pathogens in the first nucleic acid composition are different from each other and do not interfere with each other, and / or the fluorescent groups of the probes for detecting different pathogens in the second nucleic acid composition are different from each other and do not interfere with each other.

6. The composition according to any one of claims 1 to 5, characterized in that The components of the nucleic acid composition are present in a mixed form.

7. Use of the composition according to any one of claims 1 to 6 in the preparation of a kit for detecting and distinguishing viral meningitis-related pathogens.

8. A kit for detecting and distinguishing viral meningitis-related pathogens, the kit comprising the composition according to any one of claims 1 to 6.

9. The kit according to claim 8, characterized in that The kit also includes at least one of a nucleic acid releasing reagent, a nucleic acid extracting reagent, and a nucleic acid amplifying reagent.

10. Use of a composition for preparing a reagent for detecting and distinguishing viral meningitis-related pathogens, the detection comprising the following steps: 1) Extracting nucleic acid from the sample to be tested; 2) performing fluorescent quantitative PCR analysis on the nucleic acid obtained in step 1) using the composition according to any one of claims 1 to 6 or the kit according to claim 8 or 9; 3) Obtain and analyze the results.

Citation Information

Patent Citations

  • Entire gene sequence of severe fever with thrombocytopenia syndrome virus (SFTSV) and application

    CN102070704A

  • Primer group and kit for multiple PCR detection of encephalitis and meningitis related viruses

    CN106399586A

  • Method for detecting pathogens infected by cerebrospinal fluid based on PCR and nanopore sequencing

    CN113201599A

  • Alongshan virus loop-mediated isothermal amplification detection primer group, kit containing primer group and application of kit

    CN113604612A

  • System and kit for detecting multiple genes of central nervous system infection pathogens

    CN118406803A